Abstract
Stem cell factor (SCF) synergizes with other cytokines in vitro to stimulate the proliferation and differentiation of cells of the myeloid, megakaryocytic, erythroid, and lymphoid lineages. In vivo, it may play a role in engraftment after transplantation of bone marrow (BM) or peripheral blood stem cells (PBSC). Serum levels of SCF were closely monitored in 82 patients before and after allogeneic (n = 38), autologous (n = 6), or syngeneic (n = 1) BM transplantation (BMT) or autologous PBSC transplantation (PBSCT) (n = 37), respectively. SCF serum levels fluctuated around a mean in patients after allogeneic or autologous BMT or after PBSCT. In two patient subgroups (5 patients with acute myeloid leukemia [AML] and 6 patients with chronic myelogenous leukemia [CML]) with identical pretransplant conditioning regimen followed by allogeneic BMT, serum IL-6 levels significantly increased up to day +14 (p < 0.05). Correlation was not found between SCF serum levels and leukocyte or thrombocyte counts or the day of engraftment of these cell types. These data are a basis for further studies and constitute a further mosaic stone in understanding the changes in the complex cytokine network during engraftment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
